277 related articles for article (PubMed ID: 29265905)
1. Canakinumab for secondary prevention of atherosclerotic disease.
Capodanno D; Angiolillo DJ
Expert Opin Biol Ther; 2018 Feb; 18(2):215-220. PubMed ID: 29265905
[TBL] [Abstract][Full Text] [Related]
2. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.
Ridker PM; Everett BM; Thuren T; MacFadyen JG; Chang WH; Ballantyne C; Fonseca F; Nicolau J; Koenig W; Anker SD; Kastelein JJP; Cornel JH; Pais P; Pella D; Genest J; Cifkova R; Lorenzatti A; Forster T; Kobalava Z; Vida-Simiti L; Flather M; Shimokawa H; Ogawa H; Dellborg M; Rossi PRF; Troquay RPT; Libby P; Glynn RJ;
N Engl J Med; 2017 Sep; 377(12):1119-1131. PubMed ID: 28845751
[TBL] [Abstract][Full Text] [Related]
3. Canakinumab for secondary prevention of coronary artery disease.
Ortega-Paz L; Capodanno D; Angiolillo DJ
Future Cardiol; 2021 May; 17(3):427-442. PubMed ID: 33533289
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS).
Ridker PM; Thuren T; Zalewski A; Libby P
Am Heart J; 2011 Oct; 162(4):597-605. PubMed ID: 21982649
[TBL] [Abstract][Full Text] [Related]
5. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS).
Ridker PM; Libby P; MacFadyen JG; Thuren T; Ballantyne C; Fonseca F; Koenig W; Shimokawa H; Everett BM; Glynn RJ
Eur Heart J; 2018 Oct; 39(38):3499-3507. PubMed ID: 30165610
[TBL] [Abstract][Full Text] [Related]
6. Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial.
Ridker PM; MacFadyen JG; Thuren T; Everett BM; Libby P; Glynn RJ;
Lancet; 2017 Oct; 390(10105):1833-1842. PubMed ID: 28855077
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of Interleukin-1β by Canakinumab and Cardiovascular Outcomes in Patients With Chronic Kidney Disease.
Ridker PM; MacFadyen JG; Glynn RJ; Koenig W; Libby P; Everett BM; Lefkowitz M; Thuren T; Cornel JH
J Am Coll Cardiol; 2018 May; 71(21):2405-2414. PubMed ID: 29793629
[TBL] [Abstract][Full Text] [Related]
8. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial.
Ridker PM; MacFadyen JG; Everett BM; Libby P; Thuren T; Glynn RJ;
Lancet; 2018 Jan; 391(10118):319-328. PubMed ID: 29146124
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Interleukin-1β and Reduction in Atherothrombotic Cardiovascular Events in the CANTOS Trial.
Everett BM; MacFadyen JG; Thuren T; Libby P; Glynn RJ; Ridker PM
J Am Coll Cardiol; 2020 Oct; 76(14):1660-1670. PubMed ID: 33004131
[TBL] [Abstract][Full Text] [Related]
10. The cost-effectiveness of canakinumab for secondary prevention of cardiovascular disease: The Australian healthcare perspective.
Zomer E; Liew D; Tonkin A; Trauer JM; Ademi Z
Int J Cardiol; 2019 Jun; 285():1-5. PubMed ID: 30686493
[TBL] [Abstract][Full Text] [Related]
11. Interplay between hypercholesterolaemia and inflammation in atherosclerosis: Translating experimental targets into clinical practice.
Tuñón J; Bäck M; Badimón L; Bochaton-Piallat ML; Cariou B; Daemen MJ; Egido J; Evans PC; Francis SE; Ketelhuth DF; Lutgens E; Matter CM; Monaco C; Steffens S; Stroes E; Vindis C; Weber C; Hoefer IE;
Eur J Prev Cardiol; 2018 Jun; 25(9):948-955. PubMed ID: 29759006
[TBL] [Abstract][Full Text] [Related]
12. Critical roles of inflammation in atherosclerosis.
Moriya J
J Cardiol; 2019 Jan; 73(1):22-27. PubMed ID: 29907363
[TBL] [Abstract][Full Text] [Related]
13. Canakinumab in gout.
Schlesinger N
Expert Opin Biol Ther; 2012 Sep; 12(9):1265-75. PubMed ID: 22784099
[TBL] [Abstract][Full Text] [Related]
14. Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes.
Everett BM; Donath MY; Pradhan AD; Thuren T; Pais P; Nicolau JC; Glynn RJ; Libby P; Ridker PM
J Am Coll Cardiol; 2018 May; 71(21):2392-2401. PubMed ID: 29544870
[TBL] [Abstract][Full Text] [Related]
15. Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1β inhibition with canakinumab: further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis.
Ridker PM; MacFadyen JG; Thuren T; Libby P
Eur Heart J; 2020 Jun; 41(23):2153-2163. PubMed ID: 31504417
[TBL] [Abstract][Full Text] [Related]
16. Why Colchicine Should Be Considered for Secondary Prevention of Atherosclerosis: An Overview.
Nidorf SM; Thompson PL
Clin Ther; 2019 Jan; 41(1):41-48. PubMed ID: 30591286
[TBL] [Abstract][Full Text] [Related]
17. The Emerging Role of Inflammation in Cardiovascular Disease.
Martinez BK; White CM
Ann Pharmacother; 2018 Aug; 52(8):801-809. PubMed ID: 29557210
[TBL] [Abstract][Full Text] [Related]
18. Clinician's Guide to Reducing Inflammation to Reduce Atherothrombotic Risk: JACC Review Topic of the Week.
Ridker PM
J Am Coll Cardiol; 2018 Dec; 72(25):3320-3331. PubMed ID: 30415883
[TBL] [Abstract][Full Text] [Related]
19. Atherosclerosis: perspectives of anti-inflammatory therapy.
Nasonov EL; Popkova TV
Ter Arkh; 2018 May; 90(5):4-12. PubMed ID: 30701884
[TBL] [Abstract][Full Text] [Related]
20. Closing the loop on inflammation and atherothrombosis: why perform the CIRT and CANTOS trials?
Ridker PM
Trans Am Clin Climatol Assoc; 2013; 124():174-90. PubMed ID: 23874021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]